



April 5, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards, the Company having entered into a licensing agreement with Alvion Pharmaceuticals P.C. to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**



Encl: a/a

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region

Mumbai, Malaysia, Vietnam, April 05, 2022: Global pharma major, Lupin Limited (Lupin) announced today that they have entered into a licensing agreement with Alvion Pharmaceuticals P.C. (Alvion) to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.

Lupin is committed to providing new affordable treatment options to healthcare providers and patients. By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin will play a significant role in improving the quality of healthcare and access to medicines.

Commenting on the announcement, Gabriel Georgy, Regional Head Southeast Asia, Lupin said “Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost effective alternatives for patients and the healthcare system. Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region. We look forward to expanding our partnership with Alvion over the coming years.”

John Bouros, CEO, Alvion said, “Alvion is delighted to partner with Lupin for its important proprietaries and looks forward to launching the products in the Southeast Asia region. Being a leader in value-added medicines, Alvion shall support Lupin’s activities aiming to position both companies at the forefront for both molecules.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

About Alvion

Alvion Pharmaceuticals P.C. (Alvion), Athens, Greece is an international pharmaceutical company focusing on the development of added value generic medicines in various blockbuster therapeutic categories including but not limited to cardiovascular, diabetes, urinary and central nervous system. With sales in more than 50 countries, Alvion licenses its products to the leading pharmaceutical companies across the world.

For more information, please visit www.alvionpharma.com

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications, Lupin

Email: shwetamunjal@lupin.com

Marina Ioannidou

Corporate Communications Head

Email: m.ioannidou@alvionpharma.com